Serologic abnormalities associated with L-dopa therapy.
D000017:ABO Blood-Group System; D000368:Aged; D000818:Animals; D000888:Antibodies, Anti-Idiotypic; D000974:Antibodies, Antinuclear / Q000032:analysis; D000910:Antibodies, Heterophile / Q000032:analysis; D000917:Antibody Formation; D000918:Antibody Specificity; D000941:Antigens; D001323:Autoantibodies; D002986:Clinical Trials as Topic; D003165:Complement System Proteins / Q000032:analysis; D003298:Coombs Test; D004295:Dihydroxyphenylalanine / Q000008:administration & dosage / Q000009:adverse effects / Q000627:therapeutic use*; D004912:Erythrocytes / Q000276:immunology; D005260:Female; D005455:Fluorescent Antibody Technique; D006386:Hemagglutination Tests; D006801:Humans; D007074:Immunoglobulin G; D007840:Latex; D008297:Male; D008863:Microspheres; D010300:Parkinson Disease / Q000188:drug therapy; D012204:Rh-Hr Blood-Group System; D012217:Rheumatoid Factor; D012756:Sheep
D000017:ABO Blood-Group System; D000888:Antibodies, Anti-Idiotypic; D000974:Antibodies, Antinuclear; D000910:Antibodies, Heterophile; D000941:Antigens; D001323:Autoantibodies; D007074:Immunoglobulin G; D007840:Latex; D012204:Rh-Hr Blood-Group System; D004295:Dihydroxyphenylalanine; D003165:Complement System Proteins; D012217:Rheumatoid Factor